Vasopressin administration modulates anxiety-related behavior in rats

Appenrodt, E.; Schnabel, Reinhild; Schwarzberg, H

doi:10.1016/s0031-9384(98)00119-x

Cited by 79 publications

(39 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Appenrodt et al (1998), reported a decrease in anxietyrelated behavior after central or peripheral AVP administration but no effect of an AVP antagonist, while Liebsch et al (1996) found no effect of AVP on anxiety behavior, but did find a decrease in anxiety-related behavior after treatment with a V1 receptor antagonist. A third group found that AVP receptor antagonism increased anxiety-like behavior (Liebsch et al, 1996;Appenrodt et al, 1998;Everts and Koolhaas, 1999). The V1bR has also been implicated in anxiety, and treatment with an orally active V1bR antagonist resulted in a decrease in anxiety-related behavior in rats (Griebel et al, 2002).…”

Section: Discussionmentioning

confidence: 97%

Profound Impairment in Social Recognition and Reduction in Anxiety-Like Behavior in Vasopressin V1a Receptor Knockout Mice

Bielsky

Szegda

et al. 2003

Neuropsychopharmacol

476

338

View full text Add to dashboard Cite

Considerable evidence suggests that arginine vasopressin (AVP) is critically involved in the regulation of many social and nonsocial behaviors, including emotionality. The existence of two AVP receptors in the brain, namely the V1a and V1b subtypes, and the lack of clear pharmacological data using selective agonists or antagonists, make it difficult to determine which receptor is responsible for the AVP-mediated effects on behavior. Here we report the behavioral effects of a null mutation in the V1a receptor (V1aR) in male mice. Male mice lacking functional V1aR (V1aRKO) exhibit markedly reduced anxiety-like behavior and a profound impairment in social recognition. V1aRKO performed normally on spatial and nonsocial olfactory learning and memory tasks. Acute central administration of AVP robustly stimulated stereotypical scratching and autogrooming in wild-type (WT), but not V1aRKO males. AVP and oxytocin (OT) mRNA and OT receptor-binding levels were similar in WT and V1aRKO mice. Given the current findings, the V1aR may provide a novel potential pharmacological target for social and affective disorders including autism, and anxiety disorders.

show abstract

Section: Discussionmentioning

confidence: 97%

Profound Impairment in Social Recognition and Reduction in Anxiety-Like Behavior in Vasopressin V1a Receptor Knockout Mice

Bielsky

Szegda

et al. 2003

Neuropsychopharmacol

476

338

View full text Add to dashboard Cite

show abstract

“…These data give rise to the hypothesis that vasopressin acts at the level of the septum to coordinate different central functions such as learning, memory and emotionality, which, in concert, determine adequate behavioral responses of an animal to environmental demands. Whereas Bhattacharya et al [77] confirmed an anxiogenic effect of central vasopressin, Appenrodt et al [78] found anxiolytic effects of both centrally and peripherally administered vasopressin.…”

Section: Vasopressinmentioning

confidence: 98%

Neuropeptides and Anxiety-Related Behavior.

Landgraf

2001

Endocr J

View full text Add to dashboard Cite

“…In non-human mammals, the evolutionarily highly conserved neuropeptide vasopressin is a key modulator of complex emotional and social behaviours, such as attachment, 1 social exploration, recognition 2 and aggression 3 as well as anxiety, [4][5][6] fear conditioning 7 and extinction. 8 Vasopressin cell and fibre distribution patterns are highly conserved across species; 9 vasopressin production occurs in the hypothalamus, the bed nucleus of the stria terminalis and the medial amygdala, which in turn project to the lateral septum and ventral pallidum.…”

Section: Introductionmentioning

confidence: 99%

“…The 5 0 -flanking region of the gene contains three polymorphic microsatellite repeats. 13 Of these, RS3, a complex repeat of (CT) 4 -TT-(CT) 8 -(GT) n 3625 bp (base pairs) upstream of the transcription start site, with 16 different alleles in the population, and RS1, a (GATA) n repeat with 9 alleles located 553 bp from the start site, have shown nominally significant transmission disequilibrium in autism. [14][15][16] Specifically, Kim et al 16 found overtransmission of the 334 and 340 bp alleles of RS3 to probands with autism, and Wassink et al 15 found undertransmission of the 312 bp allele of RS1, whereas the 320 bp allele was overtransmitted in a subgroup of autistic probands with preserved language.…”

Section: Introductionmentioning

confidence: 99%

Genetic variants in AVPR1A linked to autism predict amygdala activation and personality traits in healthy humans

Kolachana²,

et al. 2008

View full text Add to dashboard Cite

In mammals, the neuropeptide vasopressin is a key molecule for complex emotional and social behaviours. Two microsatellite polymorphisms, RS1 and RS3, near the promoter of AVPR1A, encoding the receptor subtype most heavily implicated in behaviour regulation, have been linked to autism and behavioural traits. However, the impact of these variants on human brain function is unknown. Here we show that human amygdala function is strongly associated with genetic variation in AVPR1A. Using an imaging genetics approach in a sample of 121 volunteers studied with an emotional face-matching paradigm, we found that differential activation of amygdala is observed in carriers of risk alleles for RS3 and RS1. Alleles in RS1 previously reported to be significantly over-and undertransmitted to autistic probands showed opposing effects on amygdala activation. Furthermore, we show functional difference in human brain between short and long repeat lengths that mirror findings recently obtained in a corresponding variant in voles. Our results indicate a neural mechanism mediating genetic risk for autism through an impact on amygdala signalling and provide a rationale for exploring therapeutic strategies aimed at abnormal amygdala function in this disorder.

show abstract

Vasopressin administration modulates anxiety-related behavior in rats

Cited by 79 publications

References 24 publications

Profound Impairment in Social Recognition and Reduction in Anxiety-Like Behavior in Vasopressin V1a Receptor Knockout Mice

Profound Impairment in Social Recognition and Reduction in Anxiety-Like Behavior in Vasopressin V1a Receptor Knockout Mice

Neuropeptides and Anxiety-Related Behavior.

Genetic variants in AVPR1A linked to autism predict amygdala activation and personality traits in healthy humans

Contact Info

Product

Resources

About